Treatment of Autoimmune Hemolytic Anemia

Introduction to AIHA Treatment

The American College of Hematology recommends avoiding fluoroquinolones, such as ciprofloxacin, in patients with autoimmune hemolytic anemia (AIHA) due to the risk of exacerbating hemolysis 1
Ciprofloxacin is not used to treat AIHA as it is an antibiotic used for bacterial infections, not an immunosuppressive or hemolysis-modifying agent 2

The European Society for Medical Oncology recommends corticosteroids (prednisone 1-2 mg/kg/day for severe cases or 0.5-1 mg/kg/day for moderate cases) as the standard first-line treatment for warm AIHA, with expected response rates of 70-80% 3, 4
Folic acid supplementation (1 mg daily) should be administered to support increased erythropoiesis, as suggested by medical guidelines 5
Hemoglobin levels should be monitored weekly until steroid tapering is complete, according to clinical recommendations 5

The American College of Rheumatology suggests rituximab (375 mg/m² weekly for 4 weeks) as a preferred second-line treatment for steroid-refractory or relapsed warm AIHA, with effectiveness in 70-80% of cases 3, 4
Immunosuppressive agents such as azathioprine, cyclophosphamide, cyclosporine, or mycophenolate mofetil may be considered for refractory cases, as recommended by the European Society for Medical Oncology 3, 4, 6

Intravenous immunoglobulin (IVIG) may be considered in acute phases or cases with inadequate response to high-dose corticosteroids, as suggested by medical guidelines 3, 4

If drug-induced hemolytic anemia is suspected, the causative drug must be immediately discontinued, followed by supportive care and corticosteroids (prednisone 0.5-2 mg/kg/day) for moderate to severe cases, according to clinical recommendations 7